Reported Earnings • Nov 05
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$0.047 loss per share (down from US$0.003 profit in 3Q 2023). Revenue: US$656.8m (up 15% from 3Q 2023). Net loss: US$19.9m (down US$21.2m from profit in 3Q 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 61%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Major Estimate Revision • Oct 23
Consensus EPS estimates fall by 58% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.209 to -US$0.329 per share. Revenue forecast of US$2.55b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$14.70 unchanged from last update. Share price was steady at US$14.24 over the past week. Tillkännagivande • Oct 22
R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024 R1 RCM Inc. provided unaudited preliminary financial guidance for the fiscal quarter ended September 30, 2024. For the period, the company expects Net service revenue to be $643.0 million to $658.0 million and net loss to be $33.5 million to $17.5 million. Major Estimate Revision • Sep 05
Consensus EPS estimates upgraded to US$0.21 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.27 to -US$0.207 per share. Revenue forecast unchanged from US$2.54b at last update. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$14.73 unchanged from last update. Share price was steady at US$14.08 over the past week. Major Estimate Revision • Aug 14
Consensus EPS estimates fall by 47% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.60b to US$2.54b. Losses expected to increase from US$0.18 per share to US$0.27. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$15.63 to US$14.73. Share price was steady at US$13.98 over the past week. Reported Earnings • Aug 08
Second quarter 2024 earnings: EPS exceeds analyst expectations Second quarter 2024 results: US$0.018 loss per share (further deteriorated from US$0.002 loss in 2Q 2023). Revenue: US$627.9m (up 12% from 2Q 2023). Net loss: US$7.60m (loss widened US$6.60m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 57%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 04
Price target decreased by 10% to US$15.03 Down from US$16.71, the current price target is an average from 13 analysts. New target price is 7.0% above last closing price of US$14.05. The company is forecast to post a net loss per share of US$0.17 compared to earnings per share of US$0.0079 last year. Tillkännagivande • Jul 16
R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024 R1 RCM Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 07, 2024 Tillkännagivande • May 09
R1 RCM Inc. Revises Earnings Guidance for the Year 2024 R1 RCM Inc. revised earnings guidance for the year 2024. For the year 2024, the company expects revenue of $2,600 million to $2,640 million compared to previous guidance of $2,625 million to $2,675 million. Net operating income of $85 million to $105 million compared to previous guidance of $105 million to $135 million. Reported Earnings • May 09
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: US$0.083 loss per share (down from US$0.004 profit in 1Q 2023). Revenue: US$603.9m (up 11% from 1Q 2023). Net loss: US$35.1m (down US$36.7m from profit in 1Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 13
R1 RCM Inc., Annual General Meeting, May 22, 2024 R1 RCM Inc., Annual General Meeting, May 22, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider and approve the Election of Directors Proposal; to consider Approve our Fifth Amended and Restated 2010 Stock Incentive Plan Approve, on a non-binding, advisory basis, the compensation of our named executive officers; to consider and Ratify the selection by the audit committee of the board of directors of R1; and to consider the transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Tillkännagivande • Apr 02
R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024 R1 RCM Inc. announced that they will report Q1, 2024 results Pre-Market on May 08, 2024 Major Estimate Revision • Mar 21
Consensus EPS estimates upgraded to US$0.0021 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.0028 to -US$0.0021 per share. Revenue forecast steady at US$2.64b. Healthcare industry in the US expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at US$17.14. Share price fell 4.2% to US$13.10 over the past week. New Risk • Feb 29
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 85% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risk Large one-off items impacting financial results. Tillkännagivande • Feb 29
R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024 R1 RCM Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects to generate revenue of between $2,625 million and $2,675 million and GAAP operating income of $105 million to $135 million. Tillkännagivande • Feb 28
New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion. New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion on February 26, 2024. New Mountain Capital will acquire all of the outstanding shares of common stock of R1 RCM Inc., that are not currently owned by CoyCo 1, L.P.(“CoyCo 1”), and CoyCo 2, L.P., (“CoyCo 2” and, together with CoyCo 1, the “Investors”) or their respective affiliates for cash consideration of $13.75 per share. The Proposal provides compelling value and immediate liquidity to the Company’s public stockholders. Specifically, $13.75 per share represents a significant premium of 35% to the closing price per share of $10.17 on January 25, 2024. As of February 23, 2024, the last trading day prior to our amended request for a waiver, $13.75 represented a more than 33% premium to the 30-day volume-weighted average price of $10.31. The proposal assumes a recapitalization of the Company’s indebtedness with new debt financing to be arranged by the New Mountain Funds. The equity financing to support the Proposal would be funded by the rollover of the Investors’ existing 32% common stock ownership interest in the Company and new cash equity to be provided or arranged by the New Mountain Funds. The consummation of the transactions contemplated by the Proposal will be conditioned upon approval by both a Special Committee comprised of disinterested directors and advised by independent legal and financial advisors and the Board of Directors. This Proposal is a non-binding expression of interest only, does not constitute an offer subject to binding acceptance, and is subject to execution of mutually acceptable definitive transaction documentation. This Proposal has been approved by New Mountain’s investment committee. Ropes & Gray LLP acted as legal advisor, Goldman Sachs & Co. LLC acted as financial advisor and J.P. Morgan Securities LLC acted as financial advisor to New Mountain in the transaction. Reported Earnings • Feb 28
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: US$0.008 (up from US$0.18 loss in FY 2022). Revenue: US$2.25b (up 25% from FY 2022). Net income: US$3.30m (up US$66.6m from FY 2022). Profit margin: 0.1% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 60%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 27
Coliseum Capital Issues an Open Letter to the Board of R1 RCM On February 26, 2024, Coliseum Capital Management, LLC announced that it has issued an open letter to R1 RCM Inc.’s Board of Directors. In the letter, Coliseum Capital states that it views the offer by New Mountain Capital, L.L.C. to acquire the Company for cash consideration of $13.75 per share significantly undervalues the Company and is not in the best interest of shareholders. The letter also expresses support for the Company’s Board of Directors, management team, and strategy for shareholder value creation. Coliseum Capital encourages the Board of Directors to stand firm and require a materially higher price or reject the offer and stay the course as a public company. Tillkännagivande • Feb 16
R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer On February 15, 2024, the Board of Directors (the “Board”) of R1 RCM Inc. (the “Company”) appointed Pamela L. Spikner as principal accounting officer of the Company, effective immediately. Ms. Spikner’s appointment follows Mr. Evans’ notice to the Company on February 15, 2024 of his intent to retire by the end of the first quarter of 2024. The Company thanks Mr. Evans for his service and wishes him well in his retirement. Ms. Spikner, age 47, has served as the Company’s Chief Accounting Officer since July 2021. Prior to joining the Company, Ms. Spikner was Assistant Corporate Controller of Hill-Rom Holdings Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019. Ms. Spikner began her career with PricewaterhouseCoopers. Ms. Spikner holds a B.S. degree from Indiana University of Pennsylvania and is a certified public accountant and certified internal auditor. Tillkännagivande • Dec 20
R1 RCM Inc. Appoints Clay Ashdown as Director On December 18, 2023, the Board of Directors of R1 RCM Inc. appointed Clay Ashdown as a director of the Company, effective as of December 18, 2023, to serve until the Company’s 2024 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation, or removal. Mr. Ashdown has served as Intermountain’s Chief Financial Officer since October 23, 2023, where he has accountability over all finance and related functions at Intermountain, including finance operations, financial planning, accounting and internal audit, debt and credit management, rating agency/investor relations, payer contracting, revenue cycle, risk management, construction, and real estate. Mr. Ashdown has held numerous roles at Intermountain since joining the organization in 2000 and prior to his current role, Mr. Ashdown served as the Senior Vice President of Finance Operations. Before joining Intermountain, Mr. Ashdown worked at the public accounting firm of KPMG. Mr. Ashdown graduated from the University of Utah with a degree in Accounting and a minor in Russian, and he also earned an MBA from the University of Utah. Tillkännagivande • Dec 08
R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health. R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health for $680 million on December 5, 2023. The consideration for the acquisition will consist of $675 million in cash and the Warrant to purchase up to 12,192,000 shares of the R1 RCM Inc.’s common stock with an exercise price of $10.52 per share. R1 RCM Inc. expects to finance the cash portion of the consideration and the fees and expenses associated with the acquisition with a combination of a new incremental senior secured first lien term loan B facility, cash on hand, and borrowings under the R1 RCM Inc.’s existing revolving credit facility. Concurrently with the signing of the Purchase Agreement, the R1 RCM Inc. entered into that certain commitment letter, dated as of December 5, 2023, with JPMorgan Chase Bank, N.A., Bank of America, N.A., BofA Securities, Inc. and Barclays Bank PLC for an incremental senior secured first lien term loan B facility up to $500 million. The proceeds of the Incremental Term Loan will be used, together with cash on hand and borrowings under the R1 RCM Inc.’s existing revolving credit facility, to finance the cash consideration of the acquisition and related fees and expenses. Acclara generates ~$300M of Revenue(Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized.) and ~$25M Adjusted EBITDA(: Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized and Includes expected collective synergies or contributions to revenue and Adjusted EBITDA, as applicable, from the acquisition of Acclara and the 10-year agreement with Providence). over the last twelve months. The consummation of the acquisition is subject to certain conditions, including, among other things, the receipt of regulatory approvals, entry into the Commercial Agreements, the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, and other customary closing conditions. The consummation of the acquisition is not subject to approval from the R1 RCM Inc.’s stockholders. The acquisition is expected to close in early 2024. enterview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel. BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel. Tillkännagivande • Nov 19
R1 RCM Receives Notice Of Filing Delinquency from Nasdaq R1 RCM Inc. announced that, as anticipated, it received a letter from Nasdaq's Listing Qualifications Department indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023 (the "Form 10-Q"), the Company no longer complies with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to timely file all periodic reports with the Securities and Exchange Commission (the "Commission"). On November 13, 2023, the Company filed with the Commission a Notification of Late Filing on Form 12b-25 with respect to the Form 10-Q as a result of its determination to restate certain of its previously issued financial statements. The Nasdaq notice has no immediate effect on the listing of the Company's common stock. The Nasdaq notice states that the Company is required to submit a plan to regain compliance with Nasdaq's filing requirements for continued listing within 60 calendar days of the date of the notice. Upon acceptance of the Company's compliance plan, Nasdaq is permitted to grant an extension of up to 180 days from the Form 10-Q's filing due date for the Company to regain compliance with Nasdaq's filing requirements for continued listing. The Company intends to file the Form 10-Q with the Commission as soon as practicable. Tillkännagivande • Nov 14
R1 RCM Inc. announced delayed 10-Q filing On 11/13/2023, R1 RCM Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Price Target Changed • Nov 03
Price target decreased by 8.8% to US$19.53 Down from US$21.41, the current price target is an average from 16 analysts. New target price is 69% above last closing price of US$11.53. Stock is down 22% over the past year. The company is forecast to post earnings per share of US$0.046 next year compared to a net loss per share of US$0.16 last year. Tillkännagivande • Nov 03
R1 RCM Inc. Provides Revenue Guidance for the Year 2023 R1 RCM Inc. provided revenue guidance for the year 2023. For the year, the company expects Revenue of $2,255 million to $2,275 million. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.003 (up from US$0.071 loss in 3Q 2022). Revenue: US$572.8m (up 16% from 3Q 2022). Net income: US$1.30m (up US$30.8m from 3Q 2022). Profit margin: 0.2% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Buying Opportunity • Nov 02
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 37%. The fair value is estimated to be US$14.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Oct 26
R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors R1 RCM Inc. announced on October 19, 2023, the company received notice that Janie Wade will be resigning from the board of directors of the Company, effective October 21, 2023, in connection with her resignation from Intermountain Health. Ms. Wade was nominated to the Board by IHC Health Services Inc. (Intermountain) pursuant to the Securities Purchase Agreement, dated as of January 23, 2018, between the Company and Intermountain. Under the terms of the Securities Purchase Agreement, Intermountain is entitled to nominate another individual to the Board upon Ms. Wade’s resignation. Buying Opportunity • Oct 18
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 35%. The fair value is estimated to be US$14.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Oct 17
R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023 R1 RCM Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 02, 2023 Recent Insider Transactions Derivative • Aug 10
Lead Independent Director notifies of intention to sell stock John Henneman intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of August. If the sale is conducted around the recent share price of US$17.17, it would amount to US$859k. Since September 2022, John's direct individual holding has increased from 49.60k shares to 54.75k. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Aug 07
Price target increased by 7.8% to US$21.70 Up from US$20.13, the current price target is an average from 15 analysts. New target price is 25% above last closing price of US$17.38. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$0.064 next year compared to a net loss per share of US$0.16 last year. Tillkännagivande • Aug 03
R1 RCM Inc. Provides Earnings Guidance for the Year of 2023 R1 RCM Inc. provided earnings guidance for the year of 2023. For the year, company expects Revenue of between $2,255 million and $2,275 million and GAAP operating income of $140 million to $155 million. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0.001 (up from US$0.069 loss in 2Q 2022). Revenue: US$560.7m (up 43% from 2Q 2022). Net income: US$300.0k (up US$20.7m from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 13
R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023 R1 RCM Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 02, 2023 Recent Insider Transactions • Jun 16
Senior VP recently sold US$487k worth of stock On the 12th of June, Richard Evans sold around 29k shares on-market at roughly US$16.78 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.1m more than they bought in the last 12 months. Recent Insider Transactions • May 15
President recently sold US$327k worth of stock On the 10th of May, John Sparby sold around 20k shares on-market at roughly US$16.36 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by US$2.1m. Recent Insider Transactions Derivative • May 14
President notifies of intention to sell stock John Sparby intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of May. If the sale is conducted around the recent share price of US$15.71, it would amount to US$314k. Since September 2022, John's direct individual holding has increased from 163.82k shares to 254.82k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • May 05
R1 RCM Inc. Provides Earnings Guidance for the Year 2023 R1 RCM Inc. provided earnings guidance for the year 2023. For the period, Company expects Revenue of between $2,280 million and $2,330 million. GAAP operating income of $115 million to $140 million. Reported Earnings • May 05
First quarter 2023 earnings: EPS exceeds analyst expectations First quarter 2023 results: EPS: US$0.001 (down from US$0.10 in 1Q 2022). Revenue: US$545.6m (up 42% from 1Q 2022). Net income: US$300.0k (down 99% from 1Q 2022). Profit margin: 0.1% (down from 7.6% in 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Feb 23
CEO & Director recently bought US$1.0m worth of stock On the 21st of February, Lee Rivas bought around 72k shares on-market at roughly US$13.93 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Lee's only on-market trade for the last 12 months. Reported Earnings • Feb 17
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$0.16 loss per share (improved from US$1.86 loss in FY 2021). Revenue: US$1.81b (up 23% from FY 2021). Net loss: US$57.6m (loss narrowed 88% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Tillkännagivande • Feb 17
R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023 R1 RCM Inc. provided earnings guidance for the fiscal year 2023. for the year, the company expects revenue of between $2,280 million and $2,330 million and GAAP operating income of $115 million to $140 million. Price Target Changed • Feb 16
Price target increased by 7.3% to US$16.18 Up from US$15.07, the current price target is an average from 14 analysts. New target price is 11% above last closing price of US$14.57. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$1.86 last year. Tillkännagivande • Jan 27
R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023 R1 RCM Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 16, 2023 Major Estimate Revision • Jan 08
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.06 to -US$0.07 per share. Revenue forecast of US$1.79b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 4.8% next year. Consensus price target up from US$14.00 to US$14.57. Share price rose 14% to US$12.43 over the past week. Price Target Changed • Nov 16
Price target decreased to US$15.55 Down from US$30.73, the current price target is an average from 11 analysts. New target price is 71% above last closing price of US$9.07. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$0.057 next year compared to a net loss per share of US$1.86 last year. Price Target Changed • Nov 10
Price target decreased to US$27.82 Down from US$31.90, the current price target is an average from 11 analysts. New target price is 303% above last closing price of US$6.90. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$0.04 next year compared to a net loss per share of US$1.86 last year. 
